rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector.
- Department for International Development
- 1 January 2008
- Document Type:
- Journal Article
- Maeurer, M., Goudsmit, J., Pau, M.G., Sadoff, J., Ahmed, R.K. Andersson, J., Gaines, H., Kühlmann-Berenzon, S., Magalhaes, I., Skeiky, Y.A., Spångberg, M., Thorstensson, R., Weichold, F., Schirru, G., Mueller, S., Scanga, C., Sizemore, D.R., and Wehlin, L.
BCG vaccination, combined with adenoviral-delivered boosts, represents a reasonable strategy to augment, broaden and prolong immune protection against tuberculosis (TB). We tested BCG (SSI1331) (in 6 animals, delivered intradermally) and a recombinant (rBCG) AFRO-1 expressing perfringolysin (in 6 animals) followed by two boosts (delivered intramuscullary) with non-replicating adenovirus 35 (rAd35) expressing a fusion protein composed of Ag85A, Ag85B and TB10.4, for the capacity to induce antigen-specific cellular immune responses in rhesus macaques (Macaca mulatta). Control animals received diluent (3 animals).
Cellular immune responses were analyzed longitudinally (12 blood draws for each animal) using intracellular cytokine staining (TNF-alpha, IL-2 and IFN-gamma), T cell proliferation was measured in CD4(+), CD8alpha/beta(+), and CD8alpha/alpha(+) T cell subsets and IFN-gamma production was tested in 7 day PBMC cultures (whole blood cell assay, WBA) using Ag85A, Ag85B, TB10.4 recombinant proteins, PPD or BCG as stimuli. Animals primed with AFRO-1 showed (i) increased Ag85B-specific IFN-gamma production in the WBA assay (median >400 pg/ml for 6 animals) one week after the first boost with adenoviral-delivered TB-antigens as compared to animals primed with BCG (
AFRO-1 induces qualitatively and quantitatively different cellular immune responses as compared with BCG in rhesus macaques. Increased IFN-gamma-responses and antigen-specific T cell proliferation in the CD8alpha/alpha+ T cell subset represents a valuable marker for vaccine-take in BCG-based TB vaccine trials.
Magalhaes, I.; Sizemore, D.R.; Ahmed, R.K.; Mueller, S.; Wehlin, L.; Scanga, C.; Weichold, F.; Schirru, G.; Pau, M.G.; Goudsmit, J.; Kühlmann-Berenzon, S.; Spångberg, M.; Andersson, J.; Gaines, H.; Thorstensson, R.; Skeiky, Y.A.; Sadoff, J.; Maeurer, M. rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector. PLoS ONE (2008) 3 (11) e3790. [DOI: 10.1371/journal.pone.0003790]
Published: 1 January 2008
Document Type: Journal Article
Authors: Maeurer, M. Goudsmit, J. Pau, M.G. Sadoff, J. Ahmed, R.K. Andersson, J. Gaines, H. Kühlmann-Berenzon, S. Magalhaes, I. Skeiky, Y.A. Spångberg, M. Thorstensson, R. Weichold, F. Schirru, G. Mueller, S. Scanga, C. Sizemore, D.R. Wehlin, L.